The triple-agonist mechanism
Retatrutide (LY3437943) is a synthetic peptide that mimics three natural hormones: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon. By activating all three receptors, it targets multiple pathways involved in metabolism, appetite, and energy balance.
The three receptors
1. GLP-1 receptor
GLP-1 receptor activation is the foundation of modern weight loss medications including semaglutide (Wegovy/Ozempic). It:
- Slows gastric emptying — food stays in your stomach longer
- Signals satiety to the brain — you feel full sooner
- Enhances glucose-dependent insulin secretion
- Reduces glucagon secretion when blood sugar is high
2. GIP receptor
GIP was once thought to promote weight gain, but research now shows GIP receptor activation actually enhances the effects of GLP-1. Tirzepatide (Mounjaro/Zepbound) proved the value of dual GIP/GLP-1 agonism. GIP:
- Enhances insulin secretion after meals
- May improve lipid (fat) metabolism
- Reduces nausea — potentially improving tolerability versus pure GLP-1 agonists
- Works synergistically with GLP-1 for greater metabolic effects
3. Glucagon receptor
This is what makes retatrutide different. Glucagon is typically thought of as the hormone that raises blood sugar — the opposite of insulin. But glucagon receptor activation also:
- Increases energy expenditure (you burn more calories)
- Promotes fat breakdown (lipolysis)
- Reduces food intake through central nervous system effects
- May enhance the weight loss effects of GLP-1 and GIP agonism
Retatrutide as an "artificial peptide"
Retatrutide is a synthetic peptide designed in a laboratory. Like other modern peptide drugs such as tirzepatide (Mounjaro/Zepbound) and semaglutide (Wegovy/Ozempic), it is:
- Engineered with specific amino acid modifications to resist enzymatic breakdown
- Designed for once-weekly dosing (long half-life)
- Manufactured under strict pharmaceutical quality standards (in clinical settings)
- Not a "natural" compound — it is a precision pharmaceutical
This design approach allows the peptide to survive in the body long enough to produce sustained receptor activation with a single weekly injection, versus natural hormones that degrade within minutes.
How it compares to other weight loss medications
| Drug | Receptors | Dosing | Developer | Status |
|---|---|---|---|---|
| Retatrutide | GIP + GLP-1 + Glucagon | Weekly | Eli Lilly | Phase 3 |
| Tirzepatide | GIP + GLP-1 | Weekly | Eli Lilly | Approved |
| Semaglutide | GLP-1 | Weekly | Novo Nordisk | Approved |
| Liraglutide | GLP-1 | Daily | Novo Nordisk | Approved |
| Orforglipron | GLP-1 | Daily (oral) | Eli Lilly | Phase 3 |
Clinical development timeline
- Phase 1: Completed — established safety and dosing range in healthy volunteers
- Phase 2: Published in New England Journal of Medicine (June 2023) — showed up to ~24% weight loss at 48 weeks across dose groups.
- Phase 3 (TRIUMPH program): Five trials: TRIUMPH-1 (results reported May 2026: 30.3% weight loss), TRIUMPH-2 (T2D), TRIUMPH-3 (CV outcomes), TRIUMPH-4 (knee OA), and TRIUMPH-5 (vs semaglutide).
The first Phase 3 results (TRIUMPH-1) were reported May 2026. Additional results from TRIUMPH-2, TRIUMPH-4, and TRIUMPH-5 are expected through 2026–2027.